Company Description
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.
It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy.
The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2004 |
| IPO Date | Jun 5, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 219 |
| CEO | Ms. Renee Aguiar-Lucander |
Contact Details
Address: Kungsbron 1, D5 Stockholm, V7 SE-111 22 Sweden | |
| Phone | 46 8411 3005 |
| Website | calliditas.se |
Stock Details
| Ticker Symbol | CALT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| IPO Price | $19.50 |
| CIK Code | 0001795579 |
| CUSIP Number | 13124Q106 |
| ISIN Number | US13124Q1067 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Renee Aguiar-Lucander | Chief Executive Officer |
| Fredrik Johansson | Chief Financial Officer |
| Dr. Johan Haggblad Ph.D. | Chief Scientific Officer |
| Brian Gorman | Group General Counsel |
| Sandra Frithiof | Head of Human Resources |
| Ann-Kristin Myde BSc | Head of Clinical Development and Vice President of Project Management |
| Dr. Krassimir Mitchev | Head of Medical Affairs |
| Dr. Richard S. Philipson M.D. | Chief Medical Officer |
| Teona Johnson | Head of US Marketing |
| David Ferraro | Head of US Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2024 | 6-K | Report of foreign issuer |
| Jun 4, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| May 30, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | SC TO-C | Filing |
| May 28, 2024 | 6-K | Report of foreign issuer |
| May 28, 2024 | SC14D9C | Filing |
| May 28, 2024 | SC TO-C | Filing |
| May 23, 2024 | 6-K | Report of foreign issuer |
| May 16, 2024 | 6-K | Report of foreign issuer |
| May 6, 2024 | 6-K | Report of foreign issuer |